Purpose: Phase II trials have shown encouraging activity with ipilimumab plus fotemustine
and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary …

Background Ipilimumab improves survival of patients with metastatic melanoma, many of
whom develop brain metastases. Chemotherapy-induced release of tumour antigens might …

Long-term analysis of the NIBIT-M1 trial continues to demonstrate efficacy of the
combination of ipilimumab and fotemustine in metastatic melanoma patients with or without …

Background Combination nivolumab plus ipilimumab was efficacious in patients with
asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low …

Background Preliminary data from the ABC (76 pts, med f/u 17mo) and CheckMate 204 (94
pts, med f/u 14mo) trials showed that nivo and nivo+ ipi have activity in active melanoma …

9501 Background: We previously reported efficacy and safety of NIVO+ IPI in patients (pts)
with untreated, asymptomatic, melanoma brain metastases (MBM) from the CheckMate 204 …

Background Nivolumab monotherapy and combination nivolumab plus ipilimumab increase
proportions of patients achieving a response and survival versus ipilimumab in patients with …

9508 Background: Nivolumab (nivo) and the combination of nivo+ ipilimumab (ipi) improve
response rates (RR) and progression-free survival (PFS) compared with ipi alone in clinical …

Patients with melanoma brain metastases have a poor prognosis and historically have been
excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity …

Melanoma has a high propensity to metastasize to the brain, and this is often responsible for
treatment failure in patients with advanced disease. Melanoma patients with brain …